GT Biopharma Q2 FY26 net loss narrows to $4.5 million; operating loss widens to $4.5 million - GTBP News | RalliesGT Biopharma Q2 FY26 net loss narrows to $4.5 million; operating loss widens to $4.5 million
G
GTBP• Cash position and outlook
- Cash and cash equivalents were about $5.1 million at June 30, 2026, seen funding operations through Q4 2026.
- Phase 1 updates for GTB-3650 and GTB-5550 are expected in 2H 2026.
Quarterly results and expenses
- GT Biopharma posted a Q2 operating loss of $4.5 million, widening from $1.5 million a year earlier.
- Net loss was $4.5 million, narrowing from $30.2 million in the prior-year quarter due to a $28.7 million non-cash Greenshoe Rights liability then.
- R&D expenses climbed to $1.1 million from $0.4 million, driven by higher materials and production costs.
- SG&A expenses rose to $3.4 million from $1.1 million on higher marketing spend, with legal and consulting fees also up.
